NL-OMON23205招募中不适用
A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens
HOVON data center0 个研究点目标入组 70 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Diagnosis of symptomatic CLL (according to IWCLL guidelines, including minimal required markers (CD5/CD19/CD23 triple positive with light chain restriction))
- •Patients without prior treatment for CLL (Corticoid treatment administered due to necessary immediate intervention is allowed; within the last 10 days before start of study treatment only dose equivalents of maximum 20 mg prednisolone are permitted);
排除标准
- •♦ Current inclusion in other clinical trials
- •♦ Intolerance of exogenous protein administration;
研究者
相似试验
进行中（未招募）
不适用
A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal diseaseHyperphosphataemia in patients with end-stage renal disease receiving haemodialysisMedDRA version: 8.1Level: LLTClassification code 10020712Term: HyperphosphatemiaEUCTR2006-004959-38-DEShire Development Inc214
进行中（未招募）
1 期
A prospective multicenter, open-label, randomised, cross-over study to compare the efficacy and safety of Fosrenol and Sevelemer Hydrochloride in patients receiving hemodialysis for end stage renal diseaseHyperphosphataemia in patients with end-stage renal disease receiving haemodialysisMedDRA version: 8.1 Level: LLT Classification code 10020712 Term: HyperphosphatemiaEUCTR2006-004959-38-GBShire Development Inc214
招募中
不适用
A phase 2 study to evaluate safety and efficacy of autologous dendritic cell in Combination With TACE, in Treatment of Patients With unresectable hepatocellular carcinomaNeoplasmsKCT0000986Kyungpook National University Hospital40
招募中
不适用
Onderzoek naar de werkzaamheid van toevoeging van Cetuximab aan de combinatie van radiotherapie en Cisplatin bij patiënten met niet-kleincellig longkanker.Cetuximab, non-small lung carcinoma, cisplation, radiotherapy, locally advancedNL-OMON21439KI-AV110
进行中（未招募）
不适用
Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panretinal photocoagulation (PRP) and PRP (monotherapy) in the treatment of patients with high risk proliferative diabetic retinopathy. -EUCTR2009-014409-15-PTAIBILI - Association for Innovation and Biomedical Research on Light and Image